Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Negative 65.6%

Neg 65.6% Neu 0% Pos 0%

Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.